Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Over the last two decades, the outcomes for patients with multiple myeloma, a plasma cell
malignancy, have dramatically improved. The development of the immunomodulatory drugs …

Methods of treating, preventing and/or managing cancer as well as and diseases and
disorders associated with, or characterized by, undesired angiogenesis are disclosed …

In most countries, healthcare service budgets are not likely to support the current explosion
in the cost of new oncology drugs. Repurposing the large arsenal of approved, non …

Background Lenalidomide is a structural analogue of thalidomide with similar but more
potent biologic activity. This phase 3, placebo-controlled trial investigated the efficacy of …

Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer
and inflammatory diseases. Although the evolution of its clinical application could not have …

1Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation
Trust, Bristol, 2Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds …

Thalidomide and its analogs are immunomodulatory drugs that inhibit the production of
certain inflammatory mediators associated with cancer. In the present work, a new series of …

The approach to the patient with relapsed or relapsed/refractory multiple myeloma (RRMM)
requires a careful evaluation of the results of previous treatments, the toxicities associated …

Recent developments in the treatment of multiple myeloma have led to improvements in
response rates and to increased survival; however, relapse is inevitable in almost all …